Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status:
Terminated
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if LBH589 can help to control lower-risk
(low or intermediate-1 risk) MDS. The safety of this drug will also be studied.